Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials

por Raji, Annaswamy, Long, Jianmin, Lam, Raymond L. H., O’Neill, Edward A., Engel, Samuel S.
Publicado 2018

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

por Gallo, Silvina, Calle, Roberto A., Terra, Steven G., Pong, Annpey, Tarasenko, Lisa, Raji, Annaswamy
Publicado 2020

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

por Heymsfield, Steven B., Raji, Annaswamy, Gallo, Silvina, Liu, Jie, Pong, Annpey, Hannachi, Hakima, Terra, Steven G.
Publicado 2020

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

por Raji, Annaswamy, Xu, Zhi Jin, Lam, Raymond L. H., O’Neill, Edward A., Kaufman, Keith D., Engel, Samuel S.
Publicado 2020

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoS...

por Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy
Publicado 2018

Cross-Sectional Associations Bet ween Abdominal and Thoracic Adipose Tissue Compartments and Adiponectin and Resistin in the Framingham Heart Study

por Jain, Shilpa H., Massaro, Joseph M., Hoffmann, Udo, Rosito, Guido A., Vasan, Ramachandran S., Raji, Annaswamy, O'Donnell, Christopher J., Meigs, James B., Fox, Caroline S.
Publicado 2009

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL r...

por Pratley, Richard E., Eldor, Roy, Raji, Annaswamy, Golm, Gregory, Huyck, Susan B., Qiu, Yanping, Sunga, Sheila, Johnson, Jeremy, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2018

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized tri...

por Dagogo-Jack, Samuel, Pratley, Richard E, Cherney, David Z I, McGuire, Darren K, Cosentino, Francesco, Shih, Weichung J, Liu, Jie, Frederich, Robert, Mancuso, James P, Raji, Annaswamy, Gantz, Ira
Publicado 2021